Alignment Healthcare, Inc. (NASDAQ:ALHC) CFO Robert Thomas Freeman Sells 8,561 Shares

Alignment Healthcare, Inc. (NASDAQ:ALHC) CFO Robert Thomas Freeman sold 8,561 shares of the business’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $10.01, for a total value of $85,695.61. Following the completion of the sale, the chief financial officer now directly owns 399,429 shares of the company’s stock, valued at $3,998,284.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Robert Thomas Freeman also recently made the following trade(s):

• On Friday, September 13th, Robert Thomas Freeman sold 14,500 shares of Alignment Healthcare stock. The stock was sold at an average price of $12.00, for a total value of $174,000.00.
• On Wednesday, September 4th, Robert Thomas Freeman sold 1,650 shares of Alignment Healthcare stock. The shares were sold at an average price of $10.00, for a total value of $16,500.00.
• On Friday, July 19th, Robert Thomas Freeman sold 38,858 shares of Alignment Healthcare stock. The shares were sold at an average price of $10.01, for a total transaction of $388,968.58.
• On Wednesday, July 17th, Robert Thomas Freeman sold 22,100 shares of Alignment Healthcare stock. The shares were sold at an average price of $10.00, for a total transaction of $221,000.00.

Alignment Healthcare Price Performance

Shares of ALHC opened at $11.89 on Friday. Alignment Healthcare, Inc. has a one year low of $4.46 and a one year high of $12.36. The stock’s fifty day moving average is $9.15 and its 200-day moving average is $7.27. The company has a debt-to-equity ratio of 1.70, a quick ratio of 1.61 and a current ratio of 1.61. The firm has a market capitalization of $2.27 billion, a price-to-earnings ratio of -14.15 and a beta of 1.43.

Alignment Healthcare (NASDAQ:ALHC) last released its earnings results on Thursday, August 1st. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. Alignment Healthcare had a negative net margin of 6.85% and a negative return on equity of 101.10%. The firm had revenue of $681.29 million for the quarter, compared to analysts’ expectations of $637.66 million. During the same quarter last year, the company earned ($0.15) EPS. Alignment Healthcare’s quarterly revenue was up 47.3% on a year-over-year basis. Equities analysts anticipate that Alignment Healthcare, Inc. will post -0.67 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ALHC. Jacobs Levy Equity Management Inc. bought a new position in Alignment Healthcare during the 1st quarter valued at $918,000. Vanguard Group Inc. lifted its holdings in shares of Alignment Healthcare by 1.0% in the first quarter. Vanguard Group Inc. now owns 9,239,472 shares of the company’s stock valued at $45,828,000 after buying an additional 93,262 shares during the period. Jump Financial LLC bought a new position in Alignment Healthcare during the fourth quarter valued at about $575,000. Assenagon Asset Management S.A. grew its holdings in Alignment Healthcare by 283.9% during the first quarter. Assenagon Asset Management S.A. now owns 315,629 shares of the company’s stock worth $1,566,000 after acquiring an additional 233,417 shares during the period. Finally, Aigen Investment Management LP raised its position in Alignment Healthcare by 18.5% in the fourth quarter. Aigen Investment Management LP now owns 19,764 shares of the company’s stock worth $170,000 after acquiring an additional 3,092 shares in the last quarter. Institutional investors and hedge funds own 86.19% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on ALHC shares. Piper Sandler reissued an “overweight” rating and issued a $10.00 target price (up previously from $8.00) on shares of Alignment Healthcare in a report on Tuesday, August 6th. TD Cowen raised their price target on Alignment Healthcare from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday, August 6th. Stifel Nicolaus upped their price objective on Alignment Healthcare from $9.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Robert W. Baird raised their target price on Alignment Healthcare from $10.00 to $11.00 and gave the company an “outperform” rating in a research note on Wednesday, August 14th. Finally, Bank of America raised shares of Alignment Healthcare from a “neutral” rating to a “buy” rating and boosted their price target for the company from $7.75 to $11.00 in a report on Thursday, May 30th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $9.83.

About Alignment Healthcare

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.